Goldman Sachs
ACRS icon

Goldman Sachs’s Aclaris Therapeutics ACRS Stock Holding History

Goldman Sachs’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-150,000
Closed -$3.87M – 6298
2017
Q3 		$3.87M Buy
150,000
+15,000
+11% +$402K ﹤0.01% 3394
2017
Q2 		$3.66M Buy
135,000
+40,000
+42% +$1.09M ﹤0.01% 3319
2017
Q1 		$2.83M Buy
+95,000
New +$2.74M ﹤0.01% 3417

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Goldman Sachs's ACRS Position: Q2 2026 in Review

Goldman Sachs increased its Aclaris Therapeutics (ACRS) stake by 3.5% in Q2 2026, buying an estimated $91.3K and bringing the position to 609,158 shares worth $3.22M. The position accounts for ﹤0.01% of the portfolio, ranked #4279.

Goldman Sachs first reported a position in ACRS in Q1 2017 and has held it in 38 quarters since. The position peaked at $7.94M in Q3 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Goldman Sachs held 609,158 shares of Aclaris Therapeutics worth $3.22M as of Q2 2026.
  • Goldman Sachs bought 20,467 Aclaris Therapeutics shares in Q2 2026, an estimated $91.3K.
  • Aclaris Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4279 holding.
  • Goldman Sachs first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 38 quarters since.
  • Goldman Sachs's Aclaris Therapeutics position peaked at $7.94M in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.